Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

mit mittlerem Beobachtungszeitraum von 18 Monaten; Risikoverhältnis 0,96; obere Grenze des Konfidenzintervalls (KI) 1,16. Alogliptin ist ein Dipeptidylpeptidase-4-Inhibitor (DPP-4i) zur Behandlung von Diabetes Typ 2 bei Erwachsenen.

„Wir brauchen sicherere Diabetestherapien für Patienten mit einem erhöhten Risiko für kardiovaskuläre Erkrankungen", erklärte William B. White, MD, FASH, FAHA, FACP, leitender Forscher der EXAMINE-Studie. „Aufgrund der Auslegung der EXAMINE-Studie und der behandelten Hochrisiko-Patienten liefern diese Ergebnisse Klinikern, die Diabetespatienten mit Koronarerkrankungen behandeln, wertvolle Einblicke."

Die globale EXAMINE-Studie ist von Bedeutung, da sie die kardiovaskuläre Sicherheit bei Patienten mit erhöhtem Risiko für kardiovaskuläre Erkrankungen (KVE) ermittelt. KVE sind die Hauptursache für Morbidität und Mortalität bei Patienten mit Typ-2-Diabetes.

Es wurden insgesamt 5.380 Patienten zwischen 18 und 40 Monate nachbeobachtet. Die Anzahl an vorzeitigen Studienabbrüchen in beiden Gruppen war ähnlich. Die Patienten erhielten auch eine umfassende Standardtherapie für Diabetes Typ 2 und begleitende kardiovaskuläre Risikofaktoren.

„Das Design der EXAMINE-Studie und vor allem die gemessenen Ergebnisse machen diese Studie besonders interessant für die Diabetesbehandlung von Patienten mit hohem Risiko", sagte Ajay Ahuja, MD, Vice President, Global Medical Affairs, Takeda. „Im Laufe der vergangenen 20 Jahre hat Takeda eine solide Expertise für die Diabetesbehandlung aufgebaut und diese stets erweitert. EXAMINE zeigt unser anhaltendes Engagement für die Entwicklung neuer Produkte wie Alogliptin und für eine optimierte Behandlung des Diabetes Typ 2."

Der wichtigste sekundäre Endpunkt bestand aus den Komponenten des prim
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... HORSHAM, Pa., Sept. 20, 2011 Verilogue, the ... upcoming presentations highlighting company initiatives, including CareCoach.com, the ... healthcare dialogue between patients, caregivers and their physicians. ... conferences in September: e-Patient Connections; ...
... Sept. 20, 2011 Reportlinker.com announces that a ... catalogue: Rheumatoid Arthritis Market Forecast ... The launch of novel oral drugs and reformulations ... across the seven major markets, rising from $12bn ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Rheumatoid Arthritis Market Forecast 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on ... of heroin use and eventual overdoses. Thricefold deaths have held steady over the last ... on the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled " ... about a woman’s unfortunate experience having cosmetic skin procedures done by a family ... in blistering, swelling, bruising, and pain. This woman’s experience is only one in ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a wide variety of nutritional and wellness products, announced the addition of Vincent ... in massage therapy, active isolated stretching and the prevention and rehabilitation of injuries, ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2
... a large multi-center clinical trial, a new PSA test ... with prostate cancer -- particularly the aggressive form of ... to the two,currently available commercial PSA tests, according to ... currently available Food and Drug Administration-approved screening tests for ...
... Research institutions at 27 sites in the U.S. ... Cancer Immunotherapy Trials Network (CITN), a new initiative in ... at Fred Hutchinson Cancer Research Center. CITN will establish ... research on promising new agents that boost patients, own ...
... Mo. - Youths identified as American Indian or Alaska ... all racial groups, according to the Department of Health ... AI/AN youths in the U.S. smoke cigarettes. A University ... combat smoking should teach refusal skills to help youths ...
... , WEDNESDAY, April 6 (HealthDay News) -- Poor children with ... condition diagnosed, but this disparity has decreased in recent years, ... children in California and found that the average age of ... 1992 to 3.8 years for those born in 2000. ...
... , WEDNESDAY, April 6 (HealthDay News) -- Progesterone treatment lowers ... cervix, a new study shows. Progesterone is a naturally ... It,s believed that a short cervix -- a known risk ... a shortage of progesterone. This study included 458 women ...
... April 5 White House Press Briefing, President Barack Obama articulated ... Congress from both political parties in order to avoid a ... has matched the initial House of Representatives, proposal to make ... in areas of priority. He expressed that neither side would ...
Cached Medicine News:Health News:New prostate cancer test gives more accurate diagnosis 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 3Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 4Health News:Refusal skills help minority youths combat smoking, study finds 2Health News:Autism Diagnoses Still More Likely in Richer Neighborhoods 2Health News:Progesterone Treatment Cuts Preterm Birth Risk in Certain Women 2Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2
... needed for quality, comprehensive portable and bedside ... allows you to see up to four ... touch screen allows easy navigation through menus ... temperature., ,Standard features include two channels ...
... all-in-one anesthesia monitor., ,The Cardiocap/5 ... for use in the operating room, ... PACU. The Cardiocap/5 offers full vital ... of oxygenation and circulation to advanced ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... for intermediate care., ,The S/5 FM is ... S/5 product line., ,The S/5 FM has ... to grow. The new Patient Side Module (PSM) ... up to 12-lead ECG, NIBP, motion-tolerant SpO 2 ...
Medicine Products: